{"id":970163,"date":"2026-06-03T09:23:37","date_gmt":"2026-06-03T13:23:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/"},"modified":"2026-06-03T09:23:37","modified_gmt":"2026-06-03T13:23:37","slug":"apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/","title":{"rendered":"Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n WESTON, Fla.<\/span>, June 3, 2026<\/span> \/PRNewswire\/ – Apotex Corp. (“Apotex”) today announced the U.S. launch of sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, both of which are eligible for 180\u2011day shared exclusivity. These launches expand\u00a0Apotex’s\u00a0portfolio of treatment options for adults living with type 2 diabetes mellitus.\u00a0<\/p>\n

\n

\n \"Apotex\n <\/p>\n<\/p><\/div>\n

Type 2 diabetes affects millions of adults in the United States, and treatment often requires\u00a0long-term, reliable access to prescribed therapies.\u00a0<\/p>\n

Sitagliptin tablets are AB rated\u00a0(per FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations)\u00a0to JANUVIA\u00ae<\/sup> (Merck) and are\u00a0indicated\u00a0as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.1 \u00a0<\/sup><\/p>\n

The product is available in\u00a025 mg,\u00a050 mg, and\u00a0100 mg\u00a0strengths, packaged in 30\u2011count and 90\u2011count bottles.\u00a0<\/p>\n

Sitagliptin and metformin hydrochloride tablets are AB rated to JANUMET\u00ae<\/sup> (Merck) and are indicated as a prescription medicine that contains\u00a0a fixed-dose combination of sitagliptin and metformin hydrochloride,\u00a0sitagliptin and metformin, and can be used as an adjunct to diet and exercise to lower blood sugar in adults with type 2 diabetes.2<\/sup> The product is available in 50 mg\/500 mg\u00a0and\u00a050 mg-1,000 mg count bottles.\u00a0<\/p>\n

“Expanding access to\u00a0high-quality, affordable medicines\u00a0remain\u00a0central to our mission,” said Christine Baeder, President, Apotex\u00a0USA\u00a0and LATAM. “By introducing these products, we are seeking to strengthen the continuity of care for adults managing chronic conditions and supporting the healthcare professionals who rely on consistent, reliable treatment options for their patients.”\u00a0<\/p>\n

Both products\u00a0are being made available through U.S. wholesalers and distributors.\u00a0<\/p>\n

\n\n\n\n
\n

\n __________________________<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n 1<\/sup> Product Guide: https:\/\/www.apotex.com\/products\/us\/detail.asp?m=68610<\/a>
2 <\/sup>Product Guide: https:\/\/www.apotex.com\/products\/us\/detail.asp?m=68610<\/a>
<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\n About\u00a0Apotex<\/b>\n <\/p>\n

Apotex Corp., headquartered in Weston, Florida, is a subsidiary of Apotex Health Corp. We improve everyday access to innovative medicines and health products for millions of people around the world, offering a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally\u2014including in the United States, Mexico, and India\u2014Apotex Health Corp is the largest Canadian based pharmaceutical company and a health partner of choice across the Americas for pharmaceutical licensing and product acquisitions.<\/p>\n

\n Forward-Looking Statements<\/b>\n <\/p>\n

This press release may contain forward-looking information within the meaning of applicable securities laws. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. Forward-looking information in this news release includes statements regarding the exclusivity period of the launched products and our goal of expanding access to high quality, affordable medicines. This forward-looking information is based on a number of opinions, estimates and assumptions that, while considered by Apotex to be appropriate and reasonable as of the date of this release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, those related to the Apotex’s ability to expand its portfolio with the product launches described herein,\u00a0Apotex’s ability to expand access to\u00a0high\u2011quality, affordable medicines, Apotex’s ability to achieve its mission, Apotex’s ability to strengthen the continuity of care for adults managing chronic conditions and supporting healthcare professionals who rely on treatment options for their patients, Apotex’s ability to improve everyday access to products, Apotex becoming the partner of choice across the Americas for licensing and product acquisitions and other risks. Apotex undertakes no obligation to publicly update or review any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws.<\/p>\n

JANUVIA\u00ae<\/sup> and JANUMET\u00ae<\/sup> are registered trademarks of Merck Sharp & Dohme LLC.<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity-302789161.html<\/a><\/p>\n

SOURCE Apotex Corp.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire WESTON, Fla., June 3, 2026 \/PRNewswire\/ – Apotex Corp. (“Apotex”) today announced the U.S. launch of sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, both of which are eligible for 180\u2011day shared exclusivity. These launches expand\u00a0Apotex’s\u00a0portfolio of treatment options for adults living with type 2 diabetes mellitus.\u00a0 Type 2 diabetes affects millions of adults in the United States, and treatment often requires\u00a0long-term, reliable access to prescribed therapies.\u00a0 Sitagliptin tablets are AB rated\u00a0(per FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations)\u00a0to JANUVIA\u00ae (Merck) and are\u00a0indicated\u00a0as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.1 \u00a0 The product is available in\u00a025 mg,\u00a050 mg, and\u00a0100 mg\u00a0strengths, packaged in 30\u2011count and 90\u2011count bottles.\u00a0 Sitagliptin … <\/p>\n

Continue reading “Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-970163","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nApotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire WESTON, Fla., June 3, 2026 \/PRNewswire\/ – Apotex Corp. (“Apotex”) today announced the U.S. launch of sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, both of which are eligible for 180\u2011day shared exclusivity. These launches expand\u00a0Apotex’s\u00a0portfolio of treatment options for adults living with type 2 diabetes mellitus.\u00a0 Type 2 diabetes affects millions of adults in the United States, and treatment often requires\u00a0long-term, reliable access to prescribed therapies.\u00a0 Sitagliptin tablets are AB rated\u00a0(per FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations)\u00a0to JANUVIA\u00ae (Merck) and are\u00a0indicated\u00a0as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.1 \u00a0 The product is available in\u00a025 mg,\u00a050 mg, and\u00a0100 mg\u00a0strengths, packaged in 30\u2011count and 90\u2011count bottles.\u00a0 Sitagliptin … Continue reading "Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T13:23:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1827557\/Apotex_Corp.-Apotex_launches_sitagliptin_tablets_and_sitagliptin.jpg?id=OA2644366\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity\",\"datePublished\":\"2026-06-03T13:23:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\\\/\"},\"wordCount\":646,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1827557\\\/Apotex_Corp.-Apotex_launches_sitagliptin_tablets_and_sitagliptin.jpg?id=OA2644366\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\\\/\",\"name\":\"Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1827557\\\/Apotex_Corp.-Apotex_launches_sitagliptin_tablets_and_sitagliptin.jpg?id=OA2644366\",\"datePublished\":\"2026-06-03T13:23:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1827557\\\/Apotex_Corp.-Apotex_launches_sitagliptin_tablets_and_sitagliptin.jpg?id=OA2644366\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1827557\\\/Apotex_Corp.-Apotex_launches_sitagliptin_tablets_and_sitagliptin.jpg?id=OA2644366\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/","og_locale":"en_US","og_type":"article","og_title":"Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity - Market Newsdesk","og_description":"PR Newswire WESTON, Fla., June 3, 2026 \/PRNewswire\/ – Apotex Corp. (“Apotex”) today announced the U.S. launch of sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, both of which are eligible for 180\u2011day shared exclusivity. These launches expand\u00a0Apotex’s\u00a0portfolio of treatment options for adults living with type 2 diabetes mellitus.\u00a0 Type 2 diabetes affects millions of adults in the United States, and treatment often requires\u00a0long-term, reliable access to prescribed therapies.\u00a0 Sitagliptin tablets are AB rated\u00a0(per FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations)\u00a0to JANUVIA\u00ae (Merck) and are\u00a0indicated\u00a0as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.1 \u00a0 The product is available in\u00a025 mg,\u00a050 mg, and\u00a0100 mg\u00a0strengths, packaged in 30\u2011count and 90\u2011count bottles.\u00a0 Sitagliptin … Continue reading \"Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-03T13:23:37+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1827557\/Apotex_Corp.-Apotex_launches_sitagliptin_tablets_and_sitagliptin.jpg?id=OA2644366","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity","datePublished":"2026-06-03T13:23:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/"},"wordCount":646,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1827557\/Apotex_Corp.-Apotex_launches_sitagliptin_tablets_and_sitagliptin.jpg?id=OA2644366","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/","name":"Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1827557\/Apotex_Corp.-Apotex_launches_sitagliptin_tablets_and_sitagliptin.jpg?id=OA2644366","datePublished":"2026-06-03T13:23:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1827557\/Apotex_Corp.-Apotex_launches_sitagliptin_tablets_and_sitagliptin.jpg?id=OA2644366","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1827557\/Apotex_Corp.-Apotex_launches_sitagliptin_tablets_and_sitagliptin.jpg?id=OA2644366"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=970163"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970163\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=970163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=970163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=970163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}